Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients.
QJM
; 113(3): 181-185, 2020 Mar 01.
Article
in En
| MEDLINE
| ID: mdl-31584671
ABSTRACT
AIM:
To evaluate the relationship between dipeptidyl peptidase-4 inhibitor (DPP4i) treatment and chronic rhinosinusitis (CRS) in diabetic patients.METHODS:
We used the Longitudinal Health Insurance Database for this population-based and population-matched cohort design study. Chi-square and Wilcoxon rank-sum tests were used to evaluate the association between categorical and continuous variables, respectively. The Kaplan-Meier method with the log-rank test was used to estimate the risk of CRS and DPP4i users.RESULTS:
A total of 6198 diabetic patients were included in this cohort study. DPP4i users had a lower risk of developing CRS. The risk of CRS was significantly lower in women, patients with a Diabetes Complications Severity Index score higher than 4, patients with comorbidities, and patients with higher cumulative defined daily dose in the DPP4i group.CONCLUSION:
The results of our study demonstrate that the use of DPP4i treatment could decrease CRS risk in diabetic patients in Taiwan.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sinusitis
/
Rhinitis
/
Diabetes Mellitus, Type 2
/
Dipeptidyl-Peptidase IV Inhibitors
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
QJM
Journal subject:
MEDICINA
Year:
2020
Document type:
Article
Affiliation country:
Taiwán